SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Oxygenta Pharmaceutical Ltd

BSE: 524636 NSE: ISIN: INE102E01018
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Oxygenta Pharmaceutical Ltd belong to?
Oxygenta Pharmaceutical Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Oxygenta Pharmaceutical Ltd a good quality company?
Oxygenta Pharmaceutical Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Oxygenta Pharmaceutical Ltd undervalued or overvalued?
Oxygenta Pharmaceutical Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Oxygenta Pharmaceutical Ltd a good buy now?
Oxygenta Pharmaceutical Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd revenue growth is 175.7% for FY-2025 , which is above its 5 year CAGR of 51.4% , indicating faster growth.
Q.2 Gross Profit margin of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd Gross profit margin which is the profit after deduction of direct costs, is -9.6% for FY-2025 , which is in line with its 5 year median of -9.6% , indicating stable margins.
Q.3 Operating Profit Margin of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -8.77% for FY-2025 , which is in line with its 5 year median of -8.77% indicating stable margins.
Q.4 Net Profit Margin of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd Net Profit Margin is -8.86% for FY-2025 , is below with its 5 year median of -8.78%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin -9.6 -9.6
Operating Profit Margin -8.77 -8.77
Net Profit Margin -8.86 -8.78
Q.5 Return on Asset of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd Return on Asset is -15.24%, which is below its 5 year historical median of -6.4%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd Return on equity is 0% for FY-2025 , which is in line with its historical median of 0%, indicating the business is making similar use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd Return on capital employed is -25.62% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd Cash conversion cycle is -2 days, below its historical median of -0 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.72 1.72
ROE - -
ROCE -25.62 -25.62
Cash Conversion Cycle -2 days -
Q.9 Debt to Equity ratio of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd Debt-to-Equity ratio is -2.49 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Oxygenta Pharmaceutical Ltd?
Oxygenta Pharmaceutical Ltd Debt to cash flow from operations is 23.91 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Oxygenta Pharmaceutical Ltd?
Promoters hold 56.54% of the Oxygenta Pharmaceutical Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Oxygenta Pharmaceutical Ltd vs industry peers?
Oxygenta Pharmaceutical Ltd revenue CAGR is 51.44% , compared to the industry median CAGR of 5.51% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 109.3 138.8
Gross Profit -10.5 16.2
Operating Profit -10 16
Net Profit -10 5.3
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.72 0.79
ROE - 9.17
ROCE -25.62 11.78
Cash Conversion Cycle (days) -1.81 76

Valuation & price assessment

Q.1 Stock return of Oxygenta Pharmaceutical Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 17.2% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 17.2% 49.2% 19.8% -26.9%
Q.3 Valuation ratios of Oxygenta Pharmaceutical Ltd vs historical?
The current P/E is similar that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings - - 40.28
Price to Book -5.15 -4.55 2.77
Price to Sales 1.87 2.46 2.65
EV to EBITDA -16.61 -17.70 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Sai Life Sciences
8. Astrazeneca Pharma I
9. Piramal Pharma
10. Acutaas Chemicals
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×